Laboratory Co. of America Holdings (NYSE:LH) Holdings Boosted by CENTRAL TRUST Co

CENTRAL TRUST Co boosted its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 7.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 982 shares of the medical research company’s stock after acquiring an additional 67 shares during the period. CENTRAL TRUST Co’s holdings in Laboratory Co. of America were worth $225,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC lifted its holdings in Laboratory Co. of America by 115.7% in the third quarter. OneDigital Investment Advisors LLC now owns 6,088 shares of the medical research company’s stock worth $1,361,000 after acquiring an additional 3,265 shares during the last quarter. Alexander Randolph Advisory Inc. acquired a new stake in shares of Laboratory Co. of America in the third quarter valued at approximately $955,000. Wealthcare Advisory Partners LLC increased its stake in shares of Laboratory Co. of America by 23.9% in the fourth quarter. Wealthcare Advisory Partners LLC now owns 2,543 shares of the medical research company’s stock valued at $583,000 after purchasing an additional 490 shares during the period. Mutual of America Capital Management LLC acquired a new stake in shares of Laboratory Co. of America in the third quarter valued at approximately $2,316,000. Finally, Barclays PLC increased its stake in shares of Laboratory Co. of America by 11.8% in the third quarter. Barclays PLC now owns 620,721 shares of the medical research company’s stock valued at $138,718,000 after purchasing an additional 65,356 shares during the period. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Stock Performance

Shares of LH opened at $246.70 on Wednesday. The company has a market capitalization of $20.63 billion, a PE ratio of 47.72, a price-to-earnings-growth ratio of 1.86 and a beta of 1.07. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The company’s fifty day moving average price is $236.14 and its 200 day moving average price is $228.95.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be issued a dividend of $0.72 per share. The ex-dividend date is Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.17%. Laboratory Co. of America’s payout ratio is 55.71%.

Insider Transactions at Laboratory Co. of America

In other news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $239.42, for a total transaction of $239,420.00. Following the transaction, the executive vice president now owns 2,670 shares in the company, valued at approximately $639,251.40. The trade was a 27.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam H. Schechter sold 6,189 shares of Laboratory Co. of America stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the sale, the chief executive officer now owns 87,441 shares in the company, valued at approximately $21,289,260.27. This trade represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,572 shares of company stock worth $5,915,209. 0.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have commented on LH shares. Bank of America raised their price target on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Robert W. Baird raised their target price on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $275.00 price objective (up previously from $265.00) on shares of Laboratory Co. of America in a research note on Tuesday, December 10th. HSBC raised shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Wednesday, October 30th. Finally, UBS Group decreased their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Laboratory Co. of America presently has a consensus rating of “Moderate Buy” and a consensus price target of $263.46.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.